[Cell therapy in dilated cardiomyopathy].
A forty-one-year-old male with systolic heart failure, FC-III NYHA, clinical stage C due to dilated cardiomyopathy was submitted to an autologous transplant of the mononuclear fraction of bone marrow via coronary artery system through heart catheterism. Two months after the procedure, there was a decrease in plasma BNP and cardiac area reduction at the thorax X-ray and nuclear magnetic resonance. The echocardiogram showed decrease of the secondary regurgitation and mitral ring dilatation. There was a better performance at the ergospirometry, with increase of the maximum oxygen consumption and consequent reduction in drug therapy. The absence of adverse events characterized by clinical/hemodynamic instability, enzymatic alteration or electrocardiogram demonstrate the safety and feasibility of this procedure carried out and described with pioneering spirit in dilated cardiomyopathy.
Martino
Helena Furtado
HF
Hospital Prócardíaco, Instituto Nacional de Cardiologia Laranjeiras, Rio de Janeiro, RJ. hmartino@cardiol.br
Oliveira
Paulo Sérgio
PS
Assunção
Edmilson
E
Villela
Rita
R
Gaze
Miriam
M
Costa
Patrícia C dos Santos
PC
Souza
Fernando César Castro
FC
Weitzel
Luiz Henrique
LH
Velloso
Ana Paula R
AP
Oliveira Júnior
Amarino
A
de Carvalho
Antônio C Campos
AC
D000328:Adult; D016026:Bone Marrow Transplantation; D002303:Cardiac Output, Low / Q000209:etiology; D002311:Cardiomyopathy, Dilated / Q000175:diagnosis / Q000601:surgery*; D004452:Echocardiography; D004562:Electrocardiography; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood
D020097:Natriuretic Peptide, Brain